IM Ketamine vs Midazolam for Suicidal ER Patients

Suicidal Ideation Clinical Trial

Official title:

IM Ketamine vs Midazolam for Suicidal ER Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04640636
• Other study ID #: 8070
• Secondary ID: R01MH125155-01
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: January 2, 2021
• Est. completion date: March 2025

Study information

• Verified date: August 2023
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide. There is no approved treatment for rapid relief of suicidal thoughts although clinical trials, including ours, show relief of suicidal thoughts within hours of treatment with inexpensive, generic, sub-anesthetic ketamine. We propose a clinical trial of intramuscular ketamine in depressed ED patients with high-risk suicidality, which if successful would support a novel, easy-to-use, scalable intervention for busy emergency clinicians to implement.

Description:

Rising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide. Clinical trials, including ours, show relief of suicidal thoughts within hours of treatment with inexpensive, generic, subanesthetic ketamine. We have received NIMH R01 funding to conduct a clinical trial of intramuscular (IM) ketamine in unipolar or bipolar depressed adults who present to the CUIMC psychiatric ED with suicidality severe enough to require inpatient hospitalization as judged by ED clinical staff. Clinical staff will ask potentially eligible patients if they would like to learn more about the study, and if so, a research assistant (RA) will describe the study to the patient and perform a basic eligibility screen. Key exclusions are unstable medical problems, substance abuse, psychosis, and further detail is provided in the Inclusion/Exclusion criteria. Participants (N=90) who enroll will undergo baseline clinical ratings, brief cognitive testing, and then be randomized, double-blind, in a 2:1 ratio to a single IM injection of ketamine (n=60) or midazolam comparator (n=30). Vital signs and clinical state will be monitored until injection effects subside (approximately 2 hrs). Blood samples will be drawn at 60 minutes and 90 minutes postinjection to assay ketamine level and a genetic sample will be stored. All participants will then be admitted to the 9GN inpatient unit for standard clinical treatment with periodic research follow-up ratings through 4 weeks post-discharge from hospital. Ongoing outpatient treatment will be arranged by the inpatient clinical team. Positive results from this trial would support a novel, easy-to-use, inexpensive, and scalable intervention for busy emergency clinicians to implement.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 90
• Est. completion date: March 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• DSM5 unipolar or bipolar (I, II, or Unspecified) major depressive episode

• Presenting to emergency department and assessed by psychiatrist staff as needing inpatient treatment due to suicidality

• Participant agrees to voluntary inpatient psychiatric admission

• Beck Scale for Suicidal Ideation score of 4 or higher

Exclusion Criteria:

• Substance use disorder in past 2 weeks

• Current psychosis or mania

• Intellectual disability

• Inadequate understanding of English and/or lack of capacity for informed consent

• Pregnancy or lactation

• Medical contraindication to ketamine or midazolam

• Unstable medical or neurological illness such as uncontrolled hypertension, significant cardiac arrhythmia, unstable cerebrovascular disease. Chronic, stable medical conditions such as controlled hypertension or diabetes will not be excluded.

Related Conditions & MeSH terms

• Bipolar Disorder
• Depression
• Depression, Bipolar
• Depression, Unipolar
• Depressive Disorder
• Suicidal Ideation

Intervention

Drug:
• Ketamine hydrochloride injection
single IM injection of ketamine hydrochloride 0.5 mg/kg
• Midazolam injection
single IM injection of midazolam 0.06 mg/kg

Locations

Country	Name	City	State
United States	Comprehensive Psychiatric Emergency Department of Columbia University Medical Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
New York State Psychiatric Institute	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Scale for Suicidal Ideation (SSI)	Beck Scale for Suicidal Ideation clinician-rated version	24 hours post-treatment
Secondary	Systematic Assessment for Treatment Emergent Events (SAFTEE)	Frequency of adverse events at 24 hours post-treatment	24 hours post-treatment